Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asenapine vs Placebo and Olanzapine in Acute Schizophrenia
NCT00156117Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- May 2005
- Primary completion
- Apr 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (3 arms), sponsored by Organon & Co. Primary endpoint: Change in total PANSS score at 6 weeks. Started May 2005; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00156117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156117.